This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The economic analysis included those costs associated with ankylosing spondylitis based on different BASDAI scores. The costs and resource use data were derived from a published study with 208 patients. The costs of adalimumab, specialist visits, routine safety monitoring, X-rays, and tuberculosis skin tests were included as were the costs of nursing and physician time spent on tests, treatment for tuberculosis, and adverse events, including physician visits, liver function tests, urea and electrolytes, full blood counts, and antibiotics. The unit costs and resource quantities were derived from national sources and the literature and were reported separately, except for the costs of treating tuberculosis and the cost of ankylosing spondylitis by BADSAI score, which were reported as macro-categories. All costs were reported in UK pounds sterling (£) and discounted at an annual rate of 3.5%. The price year was not explicitly reported.
Analysis of uncertainty:
Several one-way sensitivity analyses were carried out on the key model inputs, using ranges defined by the authors. Probabilistic sensitivity analyses using a bootstrap technique were also conducted. Alternative scenarios were tested and these scenarios were briefly described.
Results
The results were reported per patient for one-year, five-year, and 30-year time horizons. Over 30 years, the expected QALYs were 8.1891 with conventional therapy and 9.2220 with adalimumab. The total per patient costs were £92,080 with conventional therapy and £115,937 with adalimumab. When adalimumab was compared with conventional therapy it resulted in an incremental cost effectiveness ratio (ICER) of £23,097 per QALY. The ICER over a one-year time horizon was £47,083 and over a five-year horizon was £26,332.
One-way sensitivity analysis, with a 30-year horizon, demonstrated that these results were robust. In all cases, the ICER was less than £30,000 per QALY.
The probabilistic sensitivity analysis indicated that, when adalimumab was compared with conventional therapy, the probability that the ICER was below £30,000 was 69.7% and the probability that it was below £40,000 was 85.6%.
The scenario analyses demonstrated that, when the indirect costs were included, the ICER reduced to £5,093 per QALY and when all patients remained on therapy regardless of their treatment response, the ICER increased to £62,679 per QALY.
